A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia

References

• National Cancer Institute. Cancer Stat Facts: Leukemia — Acute Myeloid Leukemia (AML) 2021. [cited 2021 29 April]. Available from: https://seer.cancer.gov/statfacts/html/amyl.html.
   Google Scholar
• American Cancer Society. Cancer Facts and Figures 2020. [cited 2021 29 April]. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html.
   Google Scholar
• Estey E, Othus M, Gale RP. New study-designs to address the clinical complexity of acute myeloid leukemia. Leukemia. 2019;33(3):567–569.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(6):697–712.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Bixby D, Perl A, et al. NCCN guidelines insights: acute myeloid leukemia, version 2.2021. J Natl Compr Canc Netw. 2021;19(1):16–27.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Pullarkat V, Stein AS. Venetoclax-containing regimens in acute myeloid leukemia. Ther Adv Hematol. 2021;12:2040620720986646.
   Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML. N Engl J Med. 2019;381(18):1728–1740.
   PubMed Web of Science ®Google Scholar
• Kyi C, Postow MA. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy. 2016;8(7):821–837.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K. Targeting immune signaling checkpoints in acute myeloid leukemia. J Clin Med. 2019;8(2):236.
   Web of Science ®Google Scholar
• Tamura T, Ohira M, Tanaka H, et al. Programmed death-1 ligand-1 (PDL1) expression is associated with the prognosis of patients with stage II/III gastric cancer. Anticancer Res. 2015;35(10):5369–5376.
   PubMed Web of Science ®Google Scholar
• Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–3391.
   PubMed Web of Science ®Google Scholar
• Coles SJ, Gilmour MN, Reid R, et al. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia. 2015;29(9):1952–1954.
   PubMed Web of Science ®Google Scholar
• Berthon C, Driss V, Liu J, et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother. 2010;59(12):1839–1849.
   PubMed Web of Science ®Google Scholar
• Alatrash G, Daver N, Mittendorf EA. Targeting immune checkpoints in hematologic malignancies. Pharmacol Rev. 2016;68(4):1014–1025.
   PubMed Web of Science ®Google Scholar
• Stahl M, Goldberg AD. Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets. Curr Oncol Rep. 2019;21(4):37.
   PubMed Web of Science ®Google Scholar
• Gene. Tecentriq US PI 2020. [cited 2021 29 April]. Available from: https://www.gene.com/download/pdf/tecentriq_prescribing.pdf.
   Google Scholar
• European Medical Association. Tecentriq EU SmPC 2020. [cited 2021 29 April]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq.
   Google Scholar
• Till BG, Park SI, Popplewell LL, et al. Safety and clinical activity of atezolizumab (anti-PDL1) in combination with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma. Blood. 2015;126(23):5104.
   Web of Science ®Google Scholar
• Younes A, Burke JM, Cheson BD, et al. Safety and efficacy of atezolizumab in combination with rituximab plus CHOP in previously untreated patients with diffuse large B-cell lymphoma (DLBCL): updated analysis of a phase I/II study. Blood. 2019;134(Supplement_1):2874–2874.
   Google Scholar
• European Medical Association. Guadecitabine EU SmPC 2019. [cited 2021 29 April]. Available from: https://www.ema.europa.eu/en/documents/product-information/dacogen-epar-product-information_en.pdf.
   Google Scholar
• Chung W, Kelly AD, Kropf P, et al. Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. Clin Epigenetics. 2019;11(1):106.
   PubMed Web of Science ®Google Scholar
• Issa JJ, Roboz G, Rizzieri D, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015;16(9):1099–1110.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Roboz GJ, Kropf PL, et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017;18(10):1317–1326.
   PubMed Web of Science ®Google Scholar
• Daher-Reyes GS, Merchan BM, Yee KWL. Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Expert Opin Investig Drugs. 2019;28(10):835–849.
   PubMed Web of Science ®Google Scholar
• Roboz G, Kantarjian H, Kropf P, et al. Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy. J Cancer Res. 2015;75(15 Supplement):CT321–CT321.
   Google Scholar
• Daver N, Boddu P, Garcia-Manero G, et al. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 2018;32(5):1094–1105.
   PubMed Web of Science ®Google Scholar
• Shah NJ, Kelly WJ, Liu SV, et al. Product review on the anti-PD-L1 antibody atezolizumab. Hum Vaccin Immunother. 2018;14(2):269–276.
   PubMed Web of Science ®Google Scholar
• Daver N, Garcia-Manero G, Basu S, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 2019;9(3):370–383.
   PubMed Web of Science ®Google Scholar
• Sebert M, Renneville A, Bally C, et al. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica. 2019;104(8):1565–1571.
   PubMed Web of Science ®Google Scholar
• O'Connell CL, Kropf PL, Punwani N, et al. Phase I results of a multicenter clinical trial combining guadecitabine, a DNA methyltransferase inhibitor, with atezolizumab, an immune checkpoint inhibitor, in patients with relapsed or refractory myelodysplastic syndrome or chronic myelomonocytic leukemia. Blood. 2018;132(Supplement 1):1811–1811.
   Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Response kinetics and clinical benefits of nonintensive AML therapies in the absence of morphologic response. Clin Lymphoma Myeloma Leuk. 2020;20(2):e66–e75.
   PubMed Web of Science ®Google Scholar
• Lindblad KE, Thompson J, Gui G, et al. Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. Blood. 2018;132(Supplement 1):1437–1437.
   Google Scholar
• Garcia JS, Flamand Y, Tomlinson BK, et al. Safety and efficacy of decitabine plus ipilimumab in relapsed or refractory MDS/AML in the post-BMT or transplant naïve settings. Blood. 2020;136(Supplement 1):15–17.
   Google Scholar